» Articles » PMID: 36338764

Deregulated Bile Acids May Drive Hepatocellular Carcinoma Metastasis by Inducing an Immunosuppressive Microenvironment

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Nov 7
PMID 36338764
Authors
Affiliations
Soon will be listed here.
Abstract

Bile acids (BAs) are physiological detergents that can not only promote the digestion and absorption of lipids, but also may be a potential carcinogen. The accumulation of BAs in the body can lead to cholestatic liver cirrhosis and even liver cancer. Recently, studies demonstrated that BAs are highly accumulated in metastatic lymph nodes, but not in normal healthy lymph nodes or primary tumors. Lymph node metastasis is second only to hematogenous metastasis in liver cancer metastasis, and the survival and prognosis of hepatocellular carcinoma (HCC) patients with lymph node metastasis are significantly worse than those without lymph node metastasis. Meanwhile, component of BAs was found to significantly enhance the invasive potential of HCC cells. However, it is still poorly understood how deregulated BAs fuel the metastasis process of liver cancer. The tumor microenvironment is a complex cellular ecosystem that evolves with and supports tumor cells during their malignant transformation and metastasis progression. Aberrant BAs metabolism were found to modulate tumor immune microenvironment by preventing natural killer T (NKT) cells recruitment and increasing M2-like tumor-associated macrophages (TAMs) polarization, thus facilitate tumor immune escape and HCC development. Based on these available evidence, we hypothesize that a combination of genetic and epigenetic factors in cancerous liver tissue inhibits the uptake and stimulates the synthesis of BAs by the liver, and excess BAs further promote liver carcinogenesis and HCC metastasis by inducing immunosuppressive microenvironment.

Citing Articles

Bile's Hidden Weapon: Modulating the Microbiome and Tumor Microenvironment.

Saadh M, Ahmed H, Al-Hussainy A, Kaur I, Kumar A, Chahar M Curr Microbiol. 2024; 82(1):25.

PMID: 39614901 DOI: 10.1007/s00284-024-04004-0.


Hepatocellular carcinoma cells induce γδ T cells through metabolic reprogramming into tumor-progressive subpopulation.

Xia J, Wang C, Li B Front Oncol. 2024; 14:1451650.

PMID: 39309735 PMC: 11412793. DOI: 10.3389/fonc.2024.1451650.


New insights into the mechanisms of the extracellular matrix and its therapeutic potential in anaplastic thyroid carcinoma.

Xia J, Shi Y, Chen X Sci Rep. 2024; 14(1):20977.

PMID: 39251678 PMC: 11384763. DOI: 10.1038/s41598-024-72020-y.


Integrative multi-omics characterization of hepatocellular carcinoma in Hispanic patients.

Das D, Wang X, Chiu Y, Bouamar H, Sharkey F, Lopera J J Natl Cancer Inst. 2024; 116(12):1961-1978.

PMID: 39189979 PMC: 11630563. DOI: 10.1093/jnci/djae207.


Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.

Song Y, Lau H, Zhang X, Yu J Cancer Biol Med. 2023; 21(2).

PMID: 38148326 PMC: 10884537. DOI: 10.20892/j.issn.2095-3941.2023.0394.


References
1.
Sinha S, Haileselassie Y, Nguyen L, Tropini C, Wang M, Becker L . Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. Cell Host Microbe. 2020; 27(4):659-670.e5. PMC: 8172352. DOI: 10.1016/j.chom.2020.01.021. View

2.
Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

3.
Staley C, Weingarden A, Khoruts A, Sadowsky M . Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 2016; 101(1):47-64. PMC: 5203956. DOI: 10.1007/s00253-016-8006-6. View

4.
Brodt P . Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. Clin Cancer Res. 2016; 22(24):5971-5982. DOI: 10.1158/1078-0432.CCR-16-0460. View

5.
Han L, Fan Y, Mu N, Gao S, Li F, Ji X . Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int J Med Sci. 2014; 11(2):164-71. PMC: 3894401. DOI: 10.7150/ijms.6745. View